{"id":16322,"date":"2025-05-16T14:23:56","date_gmt":"2025-05-16T14:23:56","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?p=16322"},"modified":"2025-07-30T14:11:23","modified_gmt":"2025-07-30T14:11:23","slug":"lutilisation-de-laspirine-apres-un-traitement-adjuvant-nameliore-pas-les-resultats-chez-les-patients-atteints-dun-cancer-colorectal","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/lutilisation-de-laspirine-apres-un-traitement-adjuvant-nameliore-pas-les-resultats-chez-les-patients-atteints-dun-cancer-colorectal\/","title":{"rendered":"L&rsquo;utilisation de l&rsquo;aspirine apr\u00e8s un traitement adjuvant n&rsquo;am\u00e9liore pas les r\u00e9sultats chez les patients atteints d&rsquo;un cancer colorectal"},"content":{"rendered":"<p><a href=\"https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(24)00387-X\/abstract\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Un vaste essai randomis\u00e9 de phase III<\/span><\/a><span data-contrast=\"auto\"> (ASCOLT) a r\u00e9v\u00e9l\u00e9 que la prise quotidienne d&rsquo;aspirine pendant 3 ans apr\u00e8s un traitement adjuvant standard (le traitement administr\u00e9 aux patients apr\u00e8s une intervention chirurgicale) n&rsquo;am\u00e9liorait <\/span><i><span data-contrast=\"auto\">pas<\/span><\/i><span data-contrast=\"auto\"> la survie sans r\u00e9cidive dans une population non s\u00e9lectionn\u00e9e de patients atteints d&rsquo;un cancer colorectal. Men\u00e9e dans onze pays aupr\u00e8s de 1 550 participants, l&rsquo;\u00e9tude n&rsquo;a montr\u00e9 aucune diff\u00e9rence statistiquement significative en termes de DFS \u00e0 cinq ans entre le groupe aspirine et le groupe placebo (77 % contre 74,8 %).<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><b><i><span data-contrast=\"auto\">Survie sans r\u00e9cidive<\/span><\/i><\/b><span data-contrast=\"auto\">: dur\u00e9e pendant laquelle une personne ne pr\u00e9sente aucun signe ou sympt\u00f4me de cancer apr\u00e8s un traitement.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Bien que l&rsquo;aspirine ait \u00e9t\u00e9 bien tol\u00e9r\u00e9e, avec des taux d&rsquo;effets ind\u00e9sirables similaires et aucun d\u00e9c\u00e8s li\u00e9 au traitement, les chercheurs ont conclu que l&rsquo;aspirine ne devait pas \u00eatre utilis\u00e9e en pr\u00e9vention secondaire chez la population g\u00e9n\u00e9rale atteinte d&rsquo;un cancer colorectal apr\u00e8s traitement.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Toutefois, des r\u00e9sultats ant\u00e9rieurs (par exemple, l&rsquo;essai ALASCCA) sugg\u00e8rent que l&rsquo;aspirine pourrait \u00eatre tr\u00e8s b\u00e9n\u00e9fique pour les patients pr\u00e9sentant des mutations du g\u00e8ne PIK3CA, r\u00e9duisant le risque de r\u00e9cidive de 50 %. Cela souligne le potentiel de l&rsquo;utilisation de l&rsquo;aspirine guid\u00e9e par des biomarqueurs dans les futurs traitements du cancer colorectal.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un vaste essai randomis\u00e9 de phase III (ASCOLT) a r\u00e9v\u00e9l\u00e9 que la prise quotidienne d&rsquo;aspirine pendant 3 ans apr\u00e8s un traitement adjuvant standard (le traitement administr\u00e9 aux patients apr\u00e8s une intervention chirurgicale) n&rsquo;am\u00e9liorait pas la survie sans r\u00e9cidive dans une population non s\u00e9lectionn\u00e9e de patients atteints d&rsquo;un cancer colorectal. Men\u00e9e <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/lutilisation-de-laspirine-apres-un-traitement-adjuvant-nameliore-pas-les-resultats-chez-les-patients-atteints-dun-cancer-colorectal\/\">&#8230;<\/a><\/p>\n","protected":false},"author":5,"featured_media":16404,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[42,98],"tags":[],"class_list":["post-16322","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogue","category-research-updates-fr"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/16322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=16322"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/16322\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/16404"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=16322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=16322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=16322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}